Two quinolone-susceptible Staphylococcus aureus and five quinolone-susceptible Streptococcus pneumoniae isolates were used to obtain in-vitro quinolone-resistant mutants in a multistep resistance selection process. The fluoroquinolones used were ciprofloxacin, moxifloxacin, levofloxacin, gemifloxacin, trovafloxacin and clinafloxacin. The mutagenicity of these quinolones was determined by the Salmonella and the Escherichia coli retromutation assays. All quinolone-resistant Staph. aureus mutants had at least one mutation in the grlA gene, while 86.6% of quinolone-resistant Strep. pneumoniae mutants had mutations in either or both the gyrA and parC genes. Moxifloxacin and levofloxacin selected resistant mutants later than the other quinolones, but this difference was more obvious in Staph. aureus. Accumulation of the fluoroquinolones by Staph. aureus did not explain these differences, since levofloxacin and moxifloxacin accumulated inside bacteria to the same extent as clinafloxacin and trovafloxacin. The results also showed that moxifloxacin and levofloxacin had less mutagenic potency in both mutagenicity assays, suggesting a possible relationship between the selection of resistance to quinolones and the mutagenic potency of the molecule. Furthermore, gemifloxacin selected efflux mutants more frequently than the other quinolones used. Thus, the risk of developing quinolone resistance may depend on the inoculum of the microorganism at the infection site and the concentration of the fluoroquinolone, and also on the mutagenicity of the quinolone used, with moxifloxacin and levofloxacin being the least mutagenic.
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mechanisms. In-vivo selection of quinolone resistance in bacteria is influenced by: (i) the bacterial species involved; (ii) the quinolone used; (iii) the concentration of antibiotic at the site of infection, and the ratio between this concentration and the MIC of the antibiotic for the microorganism; and (iv) the density of bacteria at the site of infection. Several studies have shown that different fluoroquinolones have different potentials to select resistance [15] [16] [17] [18] .
The mutagenic effect of nalidixic and oxolinic acids on bacteria was first demonstrated in the Salmonella mutagenicity assay [19] . Using this assay, this observation was further expanded to enoxacin and ciprofloxacin [20] , fleroxacin and enrofloxacin [21] , norfloxacin, temafloxacin, tosufloxacin and lomefloxacin [22] , and other DNA gyrase and mammalian topoisomerase II inhibitors [23] . In these studies, reversion of the hisG428 ochre mutation in strain TA102 was the genetic endpoint used, since other Salmonella tester strains failed to detect the mutagenic effect of these antibacterial compounds [20] . The mutagenic effect of nalidixic and oxolinic acids has also been detected in the Escherichia coli WP2 trp + reversion assay [24, 25] . It has been suggested that mutagenicity of quinolones could be one of the reasons for the emergence of resistant clinical strains [22, 26] . Moreover, it has been shown that adaptive mutations produce resistance to ciprofloxacin in E. coli [27] . Therefore, the present study aimed to investigate the mutagenic potency and potential of six quinolones to select for resistance in Staph. aureus and Strep. pneumoniae.
M A T E R I A L S A N D M E T H O D S Microorganisms and susceptibility testing
The study investigated two Staph. aureus and five Strep. pneumoniae clinical isolates. The MICs for the clinical isolates and the derivative mutants were determined by the NCCLS microdilution method [28] in the absence and presence of reserpine (25 mg ⁄ L). Staph. aureus was grown in MuellerHinton cation-adjusted broth, which was supplemented with lysed horse blood 5% v ⁄ v for the growth of Strep. pneumoniae.
Selection of mutants by serial passages
Resistance was selected by serial passages performed with antibiotic concentrations ranging from three doubling dilutions below to three doubling dilutions above the MIC. Based on the method described by Browne et al. 1 [29] , with slight modifications, strains were subcultured on blood agar without antibiotic pressure, instead of cation-adjusted Mueller-Hinton broth supplemented with horse blood, before the next antibiotic passage. Daily subculturing was performed until mutants with MICs that were ‡ 4· the MIC of the selected drug were obtained. The antimicrobial agents used in this study were ciprofloxacin and moxifloxacin (Bayer, Leverkusen, Germany), levofloxacin (Aventis, Madrid, Spain), gemifloxacin (GlaxoSmithKline, Harlow, UK), trovafloxacin (Pfizer Ltd, Sandwich, UK) and clinafloxacin (Parke-Davis, Ann Arbor, MI, USA). The ability of the fluoroquinolones to select resistant mutants was defined as the number of passages necessary to increase the initial MIC four-fold.
Mutations in the target genes
For each of the clinical isolates investigated, the QRDRs of the gyrA, gyrB, parC and parE genes (grlA and grlB for Staph. aureus) were amplified by PCR [5, 8] and sequenced to ensure that none of the isolates had a mutation associated with decreased susceptibility. PCR products were purified with a QiaQuick PCR purification kit (Qiagen, Hilden, Germany) and sequenced with a Big Dye terminator sequence kit v. 2.0 (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions.
Mutations in the QRDRs of the gyrA and parC genes of the mutants selected were analysed by PCR-restriction fragment length polymorphism with HinfI (Ser84 of GyrA and Ser80 of GrlA of Staph. aureus; Ser81 of GyrA and Ser79 of ParC of Strep. pneumoniae), except for some resistant mutants of Staph. aureus with a ciprofloxacin MIC of 32 or 64 mg ⁄ L, for which the QRDRs of the gyrA and grlA genes were sequenced.
Accumulation assay
The k ex and k em of each quinolone were determined for the clinical isolates of Staph. aureus with a modified fluorimetric method, as described by Mortimer and Piddock [30] and Martinez-Martinez et al. [31] . Briefly, cells were grown to the exponential phase (OD 600 of 0.6-0.7), pelleted by centrifugation, washed with phosphate-buffered saline, and then resuspended in phosphate-buffered saline to an OD 520 of 1.5. Aliquots (10 lL) of a quinolone dilution were added to 490 lL of bacterial suspension and incubated for 30 min, after which the bacterial cells were again pelleted and washed twice with phosphatebuffered saline. The final pellet was resuspended in glycineHCl, pH 3.0, and incubated for 2 h at room temperature. Finally, the cells were pelleted, the supernatant was transferred to a new tube, and the amount of fluorescence was measured. Calibration curves were also constructed for each quinolone.
Mutagenesis assays
Two reversion mutation methods were used. The Salmonella mutagenicity assay was performed by the plate incorporation method with the mutant strain TA102, as described previously, with three plates per concentration [32] . The E. coli WP2 trp + reversion assay [33] was performed with the mutant strain WP2 ⁄ pKM101 [24] according to recent recommendations [34] . The number of revertants induced was calculated by subtracting the number of spontaneous revertants obtained in the negative control for each experiment. Linear regression was calculated from the data of three independent experiments with non-toxic doses, with the mutagenic potency being the slope of the line obtained for each compound. 
Mutations in target genes
No mutations were found in the QRDRs of the gyrA, gyrB, grlA or grlB genes in the wild-type strains of Staph. aureus, whereas several different mutations were found in the wild-type strains of Strep. pneumoniae. Strain 5-1 did not have any mutation, strain 5-4 contained an alteration in ParC (R95-C), strain 5-6 had a different substitution in ParC (K137-N), strain 5-11 had an amino-acid change at ParE (I368-V), and strain 5-154 had a mutation in the amino-acid codon E85-K of the gyrA gene. All of these strains were susceptible to ciprofloxacin. All Staph. aureus mutants had a mutation in the Ser80 codon of the grlA gene, but no mutation was detected in the Ser80 codon of the gyrA gene. The gyrA and grlA genes of four mutants (4-108L13, 4-108M16, 5-61L15 and 5-61M14) with a ciprofloxacin MIC of 32 or 64 mg ⁄ L were sequenced, revealing a mutation in the Glu88 codon of the gyrA gene, producing a change from Glu to Lys. In Strep. pneumoniae, 26 of 30 resistant mutants had mutations in either gyrA or parC, or both. Twelve (40%) of the Strep. pneumoniae mutants had a double mutation, with a mutation in the Ser81 codon of the gyrA gene, plus a mutation in the Ser79 codon of the parC gene (genotype 1); nine (30%) had a mutation in the gyrA gene, but not in the parC gene (genotype 2); five (16.6%) had a mutation in the parC gene, but not in the gyrA gene (genotype 3); and four (13.3%) did not have mutations in either gene at these two codons (genotype 4). Two of the latter four strains were selected with clinafloxacin, and the remaining two with gemifloxacin ( 
Susceptibility testing
All of the resistant mutants obtained had an MIC at least four-fold higher than the MIC of the fluoroquinolone used for their selection, while the MICs of the other fluoroquinolones increased by different degrees. MICs in the presence of reserpine were also determined, to find whether an efflux system inhibited by reserpine was involved in the resistance exhibited by the mutants (Tables 1 and 2 ).
In general, the MICs for Staph. aureus did not change in the presence of reserpine, but four mutants showed a decreased MIC: strain 4-108C5 showed a four-fold decrease in the MIC of moxifloxacin; strain 4-108M16 showed a four-fold decrease in the MIC of clinafloxacin; strain 5-61G8 showed an eight-fold decrease in the MIC of ciprofloxacin; and strain 4-108T6 showed at least a four-fold decrease in the MIC to each quinolone used, with the exception of trovafloxacin (Tables 1 and 2 ).
For Strep. pneumoniae, different efflux profiles were observed in the presence of reserpine, depending on the genotype of the mutant obtained ( Table 3 ). The first group of four strains with no detectable mutations (genotype 4) comprised two strains obtained with gemifloxacin and two with clinafloxacin. Three of these four had the same efflux-pump profile, affecting the same quinolones. In all four strains, the MICs in the presence of reserpine decreased to the MICs of the respective wild-type strains, or to a maximum of twice the wild-type MIC for some quinolones. In the second group of five strains (genotype 3), there were four different profiles (Table 3) . In these strains, the MIC in the presence of reserpine decreased to a mean of 2-4 · the MIC of their respective wild-type strains. The third group (genotype 2) contained nine strains with seven different profiles (Table 3) . In this group, the MICs of the mutants in the presence of reserpine were 8-16-fold greater than those for the respective wild-type strains. Finally, the last group (genotype 1) contained 12 strains with six different efflux profiles, with 50% of the strains showing a profile characterised by a lack of any effect of reserpine on the MICs of the different
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quinolones tested. This profile was only found in this genotype group (Table 3) . These strains had the highest MICs in the presence of reserpine, with MICs that were ‡ 32-fold those of the respective wild-type strains.
Overall, the effect of reserpine on the MICs of the different fluoroquinolones was a decrease in the MIC for 76% of the strains with clinafloxacin, for 70% with ciprofloxacin, for 66% with gemifloxacin, for 46% with levofloxacin, for 30% with moxifloxacin, and for 23% with trovafloxacin.
Fluoroquinolone accumulation in Staph. aureus
The results of the accumulation assay are summarised in Table 4 . Ciprofloxacin and gemifloxacin showed the greatest accumulation, followed by moxifloxacin, and finally levofloxacin, trovafloxacin and clinafloxacin, all of which showed least accumulation at the same rate.
Mutagenicity
Mutation reversion assays with Salmonella TA102 and E. coli WP2 ⁄ pKM101 were performed using a wide range of concentrations (0.00312-0.1 lg ⁄ plate) of the six quinolones. A doseresponse relationship was observed with both assays, while quinolone toxicity was observed at certain doses, through a decrease in the number of revertants ⁄ plate and by examination of the background lawn of bacteria on the plates. In the E. coli assay, toxicity was observed with 0.025 lg ⁄ plate of moxifloxacin, and with 0.0125 lg ⁄ plate of the other quinolones. In contrast, Salmonella TA102 appeared to be less sensitive to the bactericidal activity of quinolones, as the toxic effect was detected with 0.025 lg ⁄ plate of trovafloxacin, gemifloxacin and clinafloxacin, and with 0.05 lg ⁄ plate of the other compounds. The quinolone-induced reversion at non-toxic doses is shown in Fig. 1 for both assays, and indicates that Salmonella was more sensitive than E. coli in detecting the mutagenic effect of all the quinolones tested. In order to quantify the mutagenic potential of quinolones, the mutagenic potency, expressed as the number of induced revertants ⁄ lg quinolone ⁄ plate (Table 5) , was calculated from the data shown in Fig. 1 . In the E. coli assay, levofloxacin and moxifloxacin were the least mutagenic compounds, while the rest of the quinolones were 1.5-2.1-fold more mutagenic than moxifloxacin. In the Salmonella assay, levofloxacin, moxifloxacin and ciprofloxacin were the least mutagenic compounds, while clinafloxacin, gemifloxacin and trovafloxacin were c. three-fold more mutagenic than levofloxacin.
D I S C U S S I O N
In Gram-positive bacteria, mutations at the QRDRs of both DNA gyrase and topoisomerase IV are the best-known mechanisms conferring resistance to quinolones. However, efflux systems 
Example of strain nomenclature: 5-4, number of strain; G, antibiotic used for selection; 8, number of passages required for selection. C, ciprofloxacin; M, moxifloxacin; L, levofloxacin; G, gemifloxacin; T, trovafloxacin; Clx, clinafloxacin. +, MIC decreased at least four-fold in the presence of reserpine.
-, MIC not affected in the resence of reserpine. 
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that pump quinolones out of the cells also seem to play an important role in the acquisition of resistance in Strep. pneumoniae and Staph. aureus. The mechanism by which each individual quinolone selects resistant strains is still uncertain, but may depend on the bacterial species, the quinolone used and the density of the bacteria at the infection site. The present study is the first to correlate the acquisition of quinolone resistance with the mutagenic potency of quinolones. Several reports have described the low frequency at which levofloxacin and moxifloxacin select for quinolone-resistant mutants of Strep. pneumoniae [15] [16] [17] . Nagai et al. [35] observed that ciprofloxacin selected resistant mutants of Strep. pneumoniae in a small number of steps, and that clinafloxacin and trovafloxacin behaved in a similar manner. The present study also found that more steps were required for levofloxacin and moxifloxacin to select resistant strains than were required with ciprofloxacin, gemifloxacin, trovafloxacin and clinafloxacin. Similar results were obtained with Staph. aureus, with all the quinolones selecting at least one mutation in the Ser80 codon of GrlA. There was a broad range of MICs for these mutants; for example, the ciprofloxacin MICs were 2-64 mg ⁄ L in the absence of reserpine, and 1-64 mg ⁄ L in the presence of reserpine, suggesting the possibility of other mutations in the target genes, or the presence of efflux systems not inhibited by reserpine in the mutants with higher MICs. A ciprofloxacin MIC of 32-64 mg ⁄ L was associated with mutations in the gyrA and grlA genes. A mutation in the Glu88 codon of GyrA, changing Glu to Lys, and a mutation in the Ser80 codon of GrlA, changing Ser to Phe, were detected.
The effect of the efflux systems inhibited by reserpine was less evident in Staph. aureus than in Strep. pneumoniae. Thus, only one mutant, obtained with trovafloxacin, showed a decreased MIC of each quinolone in the presence of reserpine. These results are in agreement with those of Boos et al. [15] , who selected a resistant mutant after subculturing Staph. aureus for 10 days in subinhibitory concentrations of quinolones and did not observe any inhibitory effect of reserpine on efflux systems.
The fluoroquinolones used in the present study selected resistant mutants of Strep. pneumoniae at different frequencies, with different mutations in target genes. Strains belonging to genotype 4 had at least a four-fold increase in MIC of the selecting quinolone, which was reduced to that of the wildtype strain in the presence of reserpine, suggesting the presence of an efflux system. For genotype 3, the MICs also decreased to those of the wildtype strains, or remained at only twice the MIC of the wild-type strains, in the presence of reserpine, 
suggesting that a mutation in Ser79 of ParC only generates a low level of quinolone resistance (about twice the MIC) and that the final MIC of the mutants is partially caused by the mutation in the parC gene and the overexpression of an efflux pump. For genotype 2, the MICs in the presence of reserpine remained at least eight-fold higher than those of the wild-type strains, suggesting that the final MIC is modulated by a combination of a mutation in the gyrA gene and the overexpression of a reserpine-inhibited efflux pump. The high MICs observed for this genotype suggest that a mutation in gyrA allows the bacteria to achieve higher fluoroquinolone resistance levels than those resulting from a mutation in parC.
Finally, the MICs of most of the mutants belonging to genotype 1 were not affected by reserpine, with only a two-fold decrease in MIC being observed for the strains in which reserpine did have an effect. It was interesting to note that gemifloxacin selected for the overexpression of efflux systems more frequently than did the other quinolones, as has been reported previously [15] .
Accumulation of the different quinolones was affected in different ways by the efflux systems. Thus, clinafloxacin was most affected, followed by ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, and finally trovafloxacin. Based on the different efflux profiles (Table 3) , more than one efflux system may be implicated in the acquisition of resistance to quinolones. Novel efflux systems, other than NorA and PmrA, have been described in Staph. aureus and Strep. pneumoniae [36, 37] . Furthermore, different efflux systems could have different affinities for each quinolone [36] , and the overexpression of one or more efflux systems concomitantly may affect various quinolones differently, so that the addition of reserpine may result in the demonstration of different efflux profiles.
The results obtained in this study clearly indicate that the mutagenic potency of the quinolones studied is variable, with moxifloxacin and levofloxacin having the lowest mutagenic potency. The data suggest a correlation between the mutagenic potency of each quinolone and the ability of the molecule to select for resistant mutants. Different rates of accumulation of these compounds inside bacterial cells could explain the differences found among the different quinolones in respect of both effects. However, reported data on quinolone accumulation in different species, and also the results obtained in the present study, do not support this hypothesis. Piddock and Johnson [38] reported that ciprofloxacin showed the greatest accumulation in Strep. pneumoniae cells, while levofloxacin, moxifloxacin, clinafloxacin and trovafloxacin had the same rate of accumulation. Similar results have been obtained in the present study for Staph. aureus, with ciprofloxacin and gemifloxacin clearly showing the highest accumulation, followed by moxifloxacin, and finally, levofloxacin, trovafloxacin and clinafloxacin. These data may explain why ciprofloxacin selects resistant mutants more rapidly than do other quinolones. However, they do not clarify why clinafloxacin and trovafloxacin select mutants more quickly than levofloxacin or moxifloxacin. One possibility is that the ability of each quinolone to select resistant mutants is related partially to the mutagenic potency of the quinolone. This potential depends on both the particular molecule and the bacteria. In both mutagenicity assays, trovafloxacin, gemifloxacin and clinafloxacin were the quinolones with the highest mutagenic potency, while moxifloxacin and levofloxacin were the least mutagenic, with the mutagenic potency of ciprofloxacin showing variation between the assays. Moxifloxacin and levofloxacin contain an alcoxyl group at position 8, while moxifloxacin and levofloxacin contain a methoxyl and propoxyl group, respectively. This agrees with the observation that a C8-methoxyl group in the quinolone molecule reduces the selection of resistant mutants in Mycobacterium bovis at low doses [39] . If a pathogenic strain possesses the genetic requirements for SOS mutagenesis, exposure to low concentrations of quinolones may generate mutations that confer antibiotic resistance, and these pre-existing mutations can emerge subsequently following selection as a consequence of antibiotic treatment. Thus, the risk of the development of quinolone resistance may depend on the mutagenic potency of each quinolone, with moxifloxacin and levofloxacin having the least mutagenic effect.
A C K N O W L E D G E M E N T S
The authors wish to thank B. N. Ames and M. Blanco for supplying the Salmonella and E. coli strains. This work was supported in part by FIS 02 ⁄ 0353 from 'Fondo de Investigaciones Sanitarias' from Spain, and by 2002 SGR00121 from
